Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2018
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2018
SUMMARY
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
The latest report Islet Amyloid Polypeptide - Pipeline Review, H1 2018, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle.
The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Type 2 Diabetes, Obesity, Type 1 Diabetes (Juvenile Diabetes), Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Non Alcoholic Fatty Liver Disease (NAFLD) and Osteoarthritis.
Furthermore, this report also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.
The latest report Islet Amyloid Polypeptide - Pipeline Review, H1 2018, outlays comprehensive information on the Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle.
The molecules developed by companies in Phase II, Phase I and Preclinical stages are 1, 3 and 6 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Central Nervous System and Musculoskeletal Disorders which include indications Type 2 Diabetes, Obesity, Type 1 Diabetes (Juvenile Diabetes), Non-Alcoholic Steatohepatitis (NASH), Alzheimer's Disease, Non Alcoholic Fatty Liver Disease (NAFLD) and Osteoarthritis.
Furthermore, this report also reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
- The report reviews Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development
Adocia SAS
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Co
Neurimmune Holding AG
Nordic Bioscience A/S
Prothena Corp Plc
reMYND NV
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles
(insulin human + pramlintide acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(insulin lispro + pramlintide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DACRA-042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DACRA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReS-39 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-4982 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones
Featured News & Press Releases
May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes
Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions
Aug 19, 2015: Nordic Bioscience Announces Successful Completion of Phase I study for KBP-042
May 05, 2014: reMYND’s novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models
Apr 10, 2013: Centennial Lecture features research on restoring memory and movement
Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Overview
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Companies Involved in Therapeutics Development
Adocia SAS
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Co
Neurimmune Holding AG
Nordic Bioscience A/S
Prothena Corp Plc
reMYND NV
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drug Profiles
(insulin human + pramlintide acetate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(insulin lispro + pramlintide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DACRA-042 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DACRA-089 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-056 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KBP-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NI-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ReS-39 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Target IAPP for Obesity and Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZP-4982 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Dormant Products
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Discontinued Products
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Product Development Milestones
Featured News & Press Releases
May 11, 2017: Zealand Pharma discloses amylin as the biological target under their 2014 agreement with Boehringer Ingelheim
Jan 05, 2017: Adocia Launches New Multi-Hormonal Combination Project For Treatment Of Type 1 Diabetes
Jun 08, 2016: Zealand presents new data on proprietary preclinical peptide drug candidates at the 76th Annual American Diabetes Associations Scientific Sessions
Aug 19, 2015: Nordic Bioscience Announces Successful Completion of Phase I study for KBP-042
May 05, 2014: reMYND’s novel diabetes treatment prevents - and even reverses - disease progression in pre-clinical diabetes models
Apr 10, 2013: Centennial Lecture features research on restoring memory and movement
Dec 11, 2012: University Of Alberta Medical Researchers Make Key Discovery In Fight Against Alzheimer's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Adocia SAS, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Neurimmune Holding AG, H1 2018
Pipeline by Nordic Bioscience A/S, H1 2018
Pipeline by Prothena Corp Plc, H1 2018
Pipeline by reMYND NV, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Adocia SAS, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Eli Lilly and Co, H1 2018
Pipeline by Neurimmune Holding AG, H1 2018
Pipeline by Nordic Bioscience A/S, H1 2018
Pipeline by Prothena Corp Plc, H1 2018
Pipeline by reMYND NV, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Adocia SAS
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Co
Neurimmune Holding AG
Nordic Bioscience A/S
Prothena Corp Plc
reMYND NV
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Adocia SAS
AstraZeneca Plc
Boehringer Ingelheim GmbH
Eli Lilly and Co
Neurimmune Holding AG
Nordic Bioscience A/S
Prothena Corp Plc
reMYND NV
